www.klinickafarmakologie.cz / Klin Farmakol Farm. 2025;39(2):103-110 / KLINICKÁ FARMAKOLOGIE A FARMACIE 109 PŘEHLEDOVÉ ČLÁNKY Antidepresiva v léčbě depresivní poruchy v těhotenství: Léčit, nebo neléčit? LITERATURA 1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (DSM‑5). Arlington, VA: American Psychiatric Publishing. 2013. 2. World Health Organization. International Classification of Diseases, 11th Revision (ICD‑11). Geneva: WHO. 2019. 3. Kozinszky Z, Dudas RB. Validation studies of the Edinburgh Postnatal Depression Scale for the antenatal period. J Affect Disord. 2015;176:95‑105. 4. American College of Nurse‑Midwives. A Brief Depression Screening Tool for Perinatal Clinical Practice. 2022. 5. Yin X, Sun N, Jiang N, et al. Prevalence and associated factors of antenatal depression: systematic reviews and meta‑analyses. Clin Psychol Rev. 2021;83:101932. 6. Boekhorst MGBM, Beerthuizen A, Endendijk JJ, et al. Different trajectories of depressive symptoms during pregnancy: a longitudinal population‑based study in China. J Affect Disord. 2019;248:139‑146. 7. Bao C, Jin D, Sun S, Xu L, et al. Trajectories and depressive symptoms during the perinatal period: a longitudinal population‑based study in China. 2022;13:762719. 8. Lee H, Kim KE, Kim MY, et al. Trajectories of depressive symptoms and anxiety during pregnancy and associations with pregnancy stress. Int J Environ Res Public Health. 2021;18(5):2733. 9. Gelaye B, Sanchez SE, Andrade A, et al. Association of antepartum depression, generalized anxiety, and posttraumatic stress disorder with infant birth weight and gestational age at delivery. J Affect Disord. 2020;262:310‑316. 10. Rahi M, Heikkinen T, Hartter S, et al. Placental transfer of quetiapine in relation to P‑glycoprotein activity. J Psychopharmacol. 2007;21(7):751‑756. 11. Ewing G, Tatarchuk Y, Appleby D, et al. Placental transfer of antidepressant medications: implications for postnatal adaptation syndrome. Clin Pharmacokinet. 2015;54(4):359‑370. 12. Watanabe O. Current evaluation of teratogenic and fetotoxic effects of psychotropic drugs. Seishin Shinkeigaku Zasshi. 2014;116(12):996‑1004. 13. Betcher HK, Wisner KL. Psychotropic treatment during pregnancy: research synthesis and clinical care principles. J Womens Health (Larchmt). 2020;29(3):310‑318. 14. Seifertová D, Mohr P, Strunzová V. Léčba psychofarmaky v těhotenství a laktaci. Psychiatrie Pro Praxi. 2007;3:118‑124. 15. Šebela A, Nosková E, Goetz M, et al. Psychofarmaka během těhotenství – mírní, nebo zvyšují riziko pro plod? Část druhá: stabilizátory nálady, anxiolytika. Pediatrie Pro Praxi. 2017;18(5):282‑286. 16. Cepeda MS, Kern DM, Nicholson S. Treatment resistant depression in women with peripartum depression. BMC Pregnancy Childbirth. 2019;19(1):323. 17. Ornoy A, Weinstein‑Fudim L, Ergaz Z. Antidepressants, antipsychotics, and mood stabilizers in pregnancy: what do we know and how should we treat pregnant women with depression. Birth Defects Res. 2017;109(12):933‑956. 18. Gentile S. Use of benzodiazepines in pregnancy and lactation: a review. Expert Opin Drug Saf. 2011;10(4):537‑551. 19. Shyken JM, Babbar S, et al. Benzodiazepines in pregnancy. Clin Obstet Gynecol. 2019;62(1):156‑167. 20. Tomson T, Battino D, Bonizzoni E, et al. Comparative risk of major congenital malformations with eight different antiepileptic drugs: a prospective cohort study of the EURAP registry. Lancet Neurol. 2018;17(6):530‑538. 21. Česká psychiatrická společnost. Doporučené postupy pro léčbu depresivních poruch v těhotenství a při kojení. Praha: Česká psychiatrická společnost. 2022. 22. Málová V. Esketamin. Psychiatr. praxi. 2023;24(3):194‑198. 23. Meltzer‑Brody S, Kanes S. Brexanolone injection in postpartum depression: two multicentre, double‑blind, randomised, placebo‑controlled, phase 3 trials. Lancet. 2018;392(10152):1058‑1070. 24. Grigoriadis S, VonderPorten EH, Mamisashvili L, et al. The impact of maternal depression during pregnancy on perinatal outcomes: a systematic review and meta‑analysis. J Clin Psychiatry. 2013;74(4):e321‑e341. 25. Grote NK, Bridge JA, Gavin AR, et al. A meta‑analysis of depression during pregnancy and the risk of preterm birth, low birth weight, and intrauterine growth restriction. Arch Gen Psychiatry. 2010;67(10):1012‑1024. 26. Jarde A, Morais M, Kingston D, et al. Neonatal outcomes in women with untreated antenatal depression compared with women without depression: a systematic review and meta- ‑analysis. JAMA Psychiatry. 2016;73(8):826‑837. 27. Yang J, Qu Y, Zhan Y, et al. Trajectories of depressive symptoms during pregnancy and risk of premature birth: a multicenter and prospective cohort study. Psychiatry Res. 2023;326:115251. 28. Staneva A, Bogossian F, Pritchard M, et al. The effects of maternal depression, anxiety, and perceived stress during pregnancy on preterm birth: a systematic review. Midwifery. 2015;28(3):179‑193. 29. Ghimire U, Papabathini SS, Kawuki J, et al. Depression during pregnancy and the risk of low birth weight, preterm birth and intrauterine growth restriction: an updated meta- ‑analysis. Early Hum Dev. 2021;152:105243. 30. Shenassa ED, Widemann LG, Hunt CD. Antepartum depression and preterm birth: pathophysiology, epidemiology, and disparities due to structural racism. Curr Psychiatry Rep. 2021;23(3):14. 31. Jahan N, Went TR, Sultan W, et al. Untreated depression during pregnancy and its effect on pregnancy outcomes: a systematic review. Cureus. 2021;13(8):e17251. 32. Shapiro GD, Fraser WD, Frasch MG, et al. Psychosocial stress in pregnancy and preterm birth: associations and mechanisms. J Perinat Med. 2013;41(6):631‑645. 33. Bindt C, Guo N, Bonle MT, et al. Association of antepartum and postpartum depression in Ghanaian and Ivorian women with febrile illness in their offspring: a prospective birth cohort study. Am J Epidemiol. 2013;178(9):1394‑1402. 34. Bonari L, Pinto N, Ahn E, et al. Perinatal risks of untreated depression during pregnancy. Can J Psychiatry. 2004;49(11):726‑735. 35. Mesches GA, Wisner KL, Betcher HK. A common clinical conundrum: antidepressant treatment of depression in pregnant women. Semin Perinatol. 2020;44(3):151‑229. 36. Grigoriadis S, Graves L, Peer M, et al. Maternal anxiety during pregnancy and the association with adverse perinatal outcomes: systematic review and meta‑analysis. J Clin Psychiatry. 2018;79(5):17r1201. 37. Gentile S. Untreated depression during pregnancy: short‑ and long‑term effects in offspring. A systematic review. Neuroscience. 2017;342:154‑166. 38. Weikum WM, Mayes LC, Grunau RE, et al. The impact of prenatal serotonin reuptake inhibitor (SSRI) antidepressant exposure and maternal mood on mother‑infant interactions at 3 months of age. Infant Behav Dev. 2013;36(4):485‑493. 39. Rogers A, Obst S, Teague SJ, et al. Association between maternal perinatal depression and anxiety and child and adolescent development: a meta‑analysis. JAMA Pediatr. 2020;174(11):1082‑1092. 40. Grigoriadis S, VonderPorten EH, Mamisashvili L, et al. Antidepressant exposure during pregnancy and congenital malformations: is there an association? A systematic review and meta‑analysis of the best evidence. J Clin Psychiatry. 2013;74(4):e293‑e308. 41. Bérard A, Zhao JP, Sheehy O. Antidepressant use during pregnancy and the risk of major congenital malformations in a cohort of depressed pregnant women: an updated analysis of the Quebec Pregnancy Cohort. BMJ Open. 2017;7(1):e013372. 42. Bar‑Oz B, Einarson T, Einarson A, et al. Paroxetine and congenital malformations: meta‑analysis and consideration of potential confounding factors. Clin Ther. 2007;29(5):918‑926. 43. Yang J, Qu Y, Zhan Y, et al. Trajectories of depressive symptoms during pregnancy and risk of premature birth: a multicenter and prospective cohort study. J Affect Disord. 2020;275:149‑156. 44. Venkatesh KK, Castro VM, Perlis RH, et al. Impact of antidepressant treatment during pregnancy on obstetric outcomes among women previously treated for depression: an observational cohort study. J Perinatol. 2017;37(9):1003‑1009. 45. Malm H, Sourander A, Gissler M, et al. Pregnancy complications following prenatal exposure to SSRIs or maternal psychiatric disorders: results from population‑based national register data. Am J Psychiatry. 2015;172(12):1224‑1231. 46. Huang H, Coleman S, Bridge JA, et al. A meta‑analysis of the relationship between antidepressant use in pregnancy and the risk of preterm birth and low birth weight. Hosp Psychiatry. 2014;36(1):13‑18. 47. Prady SL, Hanlon I, Fraser LK, et al. A systematic review of maternal antidepressant use in pregnancy and short‑ and long‑term offspring outcomes. Arch Womens Ment Health. 2018;21(2):127‑140. 48. Gurnot C, Martin‑Subero I, Mah SM, et al. Prenatal antidepressant exposure associated with CYP2E1 DNA methylation change in neonates. Epigenetics. 2015;10(5):361‑368. 49. El Marroun H, White T, Verhulst FC, et al. Maternal use of antidepressant or anxiolytic medication during pregnancy and childhood neurodevelopmental outcomes: a systematic review. Eur Child Adolesc Psychiatry. 2014;23(10):973‑992. 50. Korayem GB, Alanazi Y, Alanazi H, et al. Exploring women‘s perception and attitude towards antidepressant use: a cross‑sectional study. BMC Womens Health. 2024;24(1):453. 51. Ban L, Tata LJ, Fiaschi L, et al. Live and non‑live pregnancy outcomes among women with depression and anxiety: a population‑based study. PLoS One. 2012;7(8):e43462. 52. Adhikari K, Patten SB, Lee S, et al. Risk of adverse perinatal outcomes among women with pharmacologically treated and untreated depression during pregnancy: a retrospective cohort study. Paediatr Perinat Epidemiol. 2019;33(5):323‑331. 53. Marks C, Silvola R, Teal E, et al. Comparing newborn outcomes after prenatal exposure to individual antidepressants: a retrospective cohort study. Pharmacotherapy. 2021;41(11):907‑914. 54. Tharp MA, Silvola RM, Marks C, et al. Does lack of exposure to individual antidepressants at different points during pregnancy associate with reduced risk of adverse newborn outcomes? BMC Pregnancy Childbirth. 2022;22(1):926. 55. Fitton CA, Steiner MFC, Aucott L, et al. In utero exposure to antidepressant medication and neonatal and child outcomes: a systematic review. Acta Psychiatr Scand. 2020;141(1):21‑33. 56. Ng QX, Venkatanarayanan N, Ho CYX, et al. Selective serotonin reuptake inhibitors and persistent pulmonary hypertension of the newborn: an updated meta‑analysis. J Womens Health (Larchmt). 2019;28(3):331‑338. 57. Huybrechts KF, Bateman BT, Palmsten K, et al. Antidepressant use late in pregnancy and risk of persistent pulmonary hypertension of the newborn. JAMA. 2015;313(21):2142‑2149. 58. Bérard A, Sheehy O, Zhao JP, et al. SSRI and SNRI use during pregnancy and the risk of persistent pulmonary hypertension of the newborn. Br J Clin Pharmacol. 2017;83(5):1126‑1133. 59. Wurst KE, Poole C, Ephross SA, et al. First trimester paroxetine use and the prevalence of congenital, specifically cardiac, defects: a meta‑analysis of epidemiological studies. Birth Defects Res A Clin Mol Teratol. 2010;88(3):159‑170. 60. Grigoriadis S, Graves L, Peer M, et al. Benzodiazepine use during pregnancy alone or in combination with an antidepressant and congenital malformations: systematic review and meta‑analysis. J Clin Psychiatry. 2019;80(4):18r12412. 61. Chan JKN, Lee KCK, Wong CSM, et al. Prenatal antidepressant use and risk of congenital malformations: a population‑based cohort study. Psychiatry Res. 2024;339:116038. 62. Campbell KSJ, Collier AC, Irvine MA, et al. Maternal serotonin reuptake inhibitor antidepressants have acute effects on fetal heart rate variability in late gestation. Front Psychiatry. 2021;12:680177.
RkJQdWJsaXNoZXIy NDA4Mjc=